Posted on Monday, November 25, 2019 at 12:52 pm CST
Q BioMed Inc. (QBIO), announces FDA approval of its contract manufacturer IsoTherapeutics Group LLC. ITG is now cleared to manufacture the Company's FDA approved non-opioid cancer bone pain drug Strontium-89 Chloride USP.
Posted on Tuesday, November 28, 2017 at 12:38 pm CST
Q BioMed Inc., a biotechnology acceleration company, announced today that Dr. Helen Tager-Flusberg from Boston University has joined its advisory committee for QBM-001, which is being tested for pediatric developmental nonverbal disorder in toddlers within the autism spectrum disorders.
Posted on Thursday, September 21, 2017 at 9:00 am CDT
Q BioMed Inc., a biotechnology acceleration company, announced today a partnership with Sphaera Pharma to develop a new and proprietary analog of QBM-001 for pediatric developmental nonverbal disorder.
Q BioMed Inc., has closed on its final tranche of the $4,000,000 funding announced on November 30th, 2016. The company received $1,500,000 less fees on the final closing bringing the total gross funds received to date to $4MM.
Posted on Monday, February 13, 2017 at 11:44 am CST
Q BioMed, Inc. has entered into an agreement with the Oklahoma Medical Research Foundation (OMRF) and the Rajiv Gandhi Centre for Biotechnology (RGCB) to develop a chemotherapeutic technology to treat liver cancer.